. Oxygen consumption in A375-R1 melanoma cells can be inhibited by IACS-010795 with nanomolar IC50.
. In a pilot human glioblastoma study, both T/B ratios and SUVmean were highly reproducible at both 1 hour and 2 hour post injection of [ 18 F]FAZA.
Further quantification of the tumor in Figure 8 yielded both highly reproducible tumor to background ratios (T/B) and SUVmean. In the brain, sufficient clearance of the tracer background may enable 1 hour imaging, but in the rest of the body, other optimal time points may be identified. Lfc, log foldchange.
Supplemental Discussion:
A first step in the preclinical/clinical development of a new compound is validation of a robust pharmacodynamic (PD) biomarker for use in vivo (Biomark Med 1, [399] [400] [401] [402] [403] [404] [405] [406] [407] [408] [409] [410] [411] [412] [413] [414] [415] [416] [417] 2007) . The primary goal of a PD biomarker is to demonstrate, ideally in a single dose, that the compound has reached and engaged the molecular target, a necessary (but insufficient) step toward proof-of-mechanism efficacy. Note that the goal of a PD biomarker is distinct from a predictive biomarker or a prognostic biomarker. Predictive biomarkers attempt to predict the final positive efficacy of a given compound, which can be complex. Efficacy can be complicated by signaling feedback loops, off-target drug effects and drug-resistant pathways. In the case of collateral lethality, for example, predictive biomarkers would likely exist downstream of target engagement or may require both target engagement and documentation of lack of relevant compensatory processes. By contrast, prognostic biomarkers are utilized to stratify patient survival and risks to patients prior to therapeutic interventions. As a special case, PD biomarkers are useful as negative predictors in preclinical studies once the human maximum tolerated dose (MTD) is known and may be useful for personalized dosing in patients. For example, for molecular-targeted therapy in patients, if a threshold for target engagement is not achieved as assessed by the PD biomarker prior to the individual patient exhibiting dose limiting toxicity, then the patient might be switched to an alternative therapy.
